# Safety and Immunogenicity Study of SCB-1019T in Children

> **NCT06666179** · PHASE1 · WITHDRAWN · sponsor: **Clover Biopharmaceuticals AUS Pty**

## Conditions studied

- RSV Infection

## Interventions

- **BIOLOGICAL:** low dose SCB-1019T
- **BIOLOGICAL:** adjuvanted low dose SCB-1019T
- **BIOLOGICAL:** high dose SCB-1019T
- **BIOLOGICAL:** adjuvanted high dose SCB-1019T
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06666179
- **Lead sponsor:** Clover Biopharmaceuticals AUS Pty
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-10
- **Primary completion:** 2026-06
- **Final completion:** 2026-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was terminated during the EC submission process prior to the enrolment
- **Last updated:** 2024-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06666179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06666179, "Safety and Immunogenicity Study of SCB-1019T in Children". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT06666179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*